Group 1: Financial Performance - In Q1 2024, the company's revenue and profit experienced a decline compared to the previous year due to special events impacting market demand [1] - The sales gross margin for Q1 2024 was reported at 40.15%, with plans to maintain a high gross margin in the future [2] Group 2: Business Strategy - The company aims for double-digit growth in 2024, focusing on large customer strategies and increasing participation in industry exhibitions and forums [1] - The company plans to enhance its own brand promotion, particularly for its brand "Baihe Kang" [1] Group 3: Market Demand and Customer Base - The current business growth relies on major domestic single-product customers and numerous high-growth clients, with a strong ability to customize and deliver personalized products [2] - The company intends to increase the revenue share from its own brand business while maintaining a stable development of contract manufacturing [2] Group 4: Future Plans and Industry Trends - A stock incentive plan is expected to be introduced to cover core management and key personnel, aiming for maximum motivational effect [2] - The company is exploring the competitive landscape, considering whether industry concentration will shift towards brand or OEM sides, with new entrants likely favoring a light asset model [2][3]

Financial Performance - The company's operating revenue for Q1 2024 was ¥188,638,808.65, representing a decrease of 18.68% compared to the same period last year[4]. - The net profit attributable to shareholders was ¥34,850,457.04, down 22.18% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was ¥34,730,392.94, a decrease of 20.46% compared to the previous year[4]. - Total revenue for Q1 2024 was ¥188,638,808.65, a decrease of 18.6% compared to ¥231,965,285.09 in Q1 2023[17]. - Net profit for Q1 2024 was ¥34,850,457.04, a decline of 22.2% from ¥44,783,221.82 in Q1 2023[18]. - Operating profit for Q1 2024 was ¥39,864,164.04, down 22.5% from ¥51,434,864.07 in Q1 2023[18]. - The basic earnings per share were ¥0.54, reflecting a decrease of 22.86% year-on-year[4]. - Basic and diluted earnings per share for Q1 2024 were both ¥0.54, down from ¥0.70 in Q1 2023, reflecting a decline of 22.9%[19]. Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 160.91%, amounting to ¥26,771,614.42, primarily due to a reduction in material payments[4][7]. - Cash inflow from operating activities for Q1 2024 was ¥186,142,054.34, a decrease of 17.7% from ¥226,025,236.83 in Q1 2023[22]. - The net cash flow from operating activities increased to ¥26,771,614.42 in Q1 2024, compared to ¥10,261,019.33 in Q1 2023, marking a significant improvement[22]. - The company's cash and cash equivalents at the end of Q1 2024 were ¥1,090,598,121.97, down from ¥1,135,618,048.31 at the beginning of the quarter[23]. - The total cash outflow from investing activities in Q1 2024 was ¥74,733,254.38, compared to ¥67,899,071.89 in Q1 2023, indicating increased investment activity[23]. - The company reported a net cash outflow from financing activities of ¥641,077.83 in Q1 2024, reflecting cash used for financing purposes[23]. - The company reported a net cash decrease of ¥45.12 million in Q1 2024, an improvement from a decrease of ¥56.16 million in Q1 2023[34]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,741,776,175.48, a slight increase of 0.32% from the end of the previous year[4]. - The company's total assets increased to ¥1,741,776,175.48 in Q1 2024 from ¥1,736,159,386.58 in Q1 2023, reflecting a growth of 0.1%[14]. - Total liabilities decreased to ¥193,067,939.64 in Q1 2024 from ¥221,695,214.78 in Q1 2023, a reduction of 12.9%[15]. - The total liabilities decreased to ¥189.93 million in Q1 2024 from ¥221.66 million in Q1 2023, a reduction of approximately 14.4%[27]. - The total equity increased to ¥1,596.32 million in Q1 2024, up from ¥1,559.47 million in Q1 2023, reflecting a growth of 2.4%[27]. - The company's total assets amounted to ¥1,786.26 million in Q1 2024, slightly up from ¥1,781.13 million in Q1 2023[27]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,091[9]. - The equity attributable to shareholders increased by 2.26% to ¥1,548,708,235.84 compared to the end of the previous year[4]. Research and Development - Research and development expenses for Q1 2024 were ¥7,382,842.54, an increase of 9.1% compared to ¥6,765,422.11 in Q1 2023[18]. - Research and development expenses rose to ¥7.38 million in Q1 2024, compared to ¥6.77 million in Q1 2023, indicating a 9.0% increase[29]. Strategic Focus - The company aims to enhance its market presence and is focusing on new product development and technology advancements[16].

Dividend Distribution - The company plans to distribute a cash dividend of 7.50 RMB per 10 shares, totaling approximately 47,234,700 RMB (including tax) based on the total share capital of 62,979,600 shares after repurchase adjustments[6]. - The total cash dividend for 2023, including share repurchase amounts, is 85,471,828.76 RMB (including tax), representing 50.56% of the net profit attributable to shareholders[7]. - The profit distribution proposal is subject to approval at the company's shareholder meeting[8]. - The company has established a cash dividend policy that mandates a minimum of 10% of the distributable profit to be distributed as cash dividends when conditions are met[144]. - The total dividend amount, including cash buybacks, reached 85,471,828.76 RMB, representing 50.56% of the net profit attributable to ordinary shareholders in the consolidated financial statements[148]. Financial Performance - In 2023, the company's operating revenue reached approximately RMB 871.25 million, representing a year-on-year increase of 20.12% compared to RMB 725.33 million in 2022[27]. - The net profit attributable to shareholders was approximately RMB 169.07 million, an increase of 22.65% from RMB 137.84 million in 2022[27]. - The basic earnings per share rose to RMB 2.64, reflecting a growth of 20.00% compared to RMB 2.20 in the previous year[27]. - The net cash flow from operating activities increased by 26.78% to RMB 193.85 million, up from RMB 152.91 million in 2022[27]. - The total assets of the company at the end of 2023 were approximately RMB 1.74 billion, a 4.46% increase from RMB 1.66 billion at the end of 2022[27]. Research and Development - The company's R&D investment in 2023 was ¥30,948,500, accounting for 3.55% of total revenue, which is a 37.51% increase compared to the previous year[37]. - The company obtained 147 health food registration certificates and 4 authorized invention patents in 2023, enhancing its competitive advantage in R&D[37]. - The total number of R&D personnel is 150, making up 13.39% of the total workforce[84]. Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[27]. - The company is focusing on developing new product lines, including infant supplementary foods and sports nutrition products, to strengthen its market position[63]. - The company plans to implement a "big single product strategy" in 2024, focusing on affordable and high-volume sales through deep cooperation with key offline pharmacies[108]. - The company aims to expand its self-owned brand channel layout and explore more precise private domain e-commerce operations in 2024[39]. Compliance and Governance - The company has received a standard unqualified audit report from Rongcheng Accounting Firm[5]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[11]. - The company has not violated decision-making procedures for external guarantees[11]. - The company has maintained a clear and transparent cash dividend policy, ensuring that minority shareholders have opportunities to express their opinions[146]. Operational Efficiency - The company is focused on enhancing its operational efficiency and exploring potential mergers and acquisitions to strengthen its market position[27]. - The company has implemented a quality control system certified by 12 different international standards, ensuring product safety and reliability[61]. - The company has established a robust talent development strategy, focusing on enhancing the capabilities of its marketing team, particularly for its own brand sales team, through regular training and a learning organization[41]. Risk Management - The company emphasizes that forward-looking statements do not constitute substantive commitments to investors, highlighting investment risks[10]. - The company has not disclosed any significant risks that could affect the authenticity, accuracy, and completeness of the annual report[11]. - The company faces risks related to technology leakage and core talent loss, which could impact its competitive edge and business development[112]. Corporate Social Responsibility - Total donations for public welfare projects amounted to 520,000 CNY, specifically for the 2023 Charity Day event[156]. - The company has not disclosed a separate social responsibility or ESG report[157]. - There are no measures reported for carbon emission reduction during the reporting period[158]. Shareholder Commitments - The controlling shareholder has pledged to avoid any business activities that may compete with the company's operations, ensuring that any related income will belong to the company[167]. - The company will disclose any related transactions in accordance with regulatory requirements and will not use such transactions to transfer profits[169]. - The company has committed to measures to ensure the fulfillment of diluted immediate return commitments by its directors and senior management[174].

一、独立董事的基本情况 本人作为公司独立董事，属于行业内专业人士，任职上市公司独立董事家数 不超过 3 家。 本人在董事会专门委员会的任职情况如下：提名委员会主任委员、薪酬与考 核委员会委员。 威海百合生物技术股份有限公司 2023 年度独立董事述职度报告（李秉胜） 各位股东及股东代表： 作为威海百合生物技术股份有限公司（以下简称"公司"）的独立董事，我 在职期间严格按照《公司法》《上市公司治理准则》《上市公司独立董事管理办 法》等法律法规和公司《公司章程》《独立董事工作细则》等的规定和要求，忠 实、勤勉履职，积极出席相关会议，认真审议各项议案，对公司重大事项发表相 关意见，有效维护公司及全体股东尤其是中小股东的合法权益。现就 2023 年度 （以下简称"报告期内"）履职情况报告如下： （一）个人工作履历、专业背景及任职情况 1962 年出生，中国国籍，无永久境外居留权，博士研究生学历，曾任济南 军区总医院医师、主任医师，现任解放军 960 医院主任医师，现任公司独立董事。 （二）独立性的情况说明 作为公司独立董事，我符合《上市公司独立董事管理办法》第六条规定的独 立性要求，不存在影响独立性的情况。 二、独立 ...

审计报告 威海百合生物技术股份有限公司 容诚审字[2024]251Z0003 号 容诚会计师事务所(特殊普通合伙) 中国·北京 目 录 | 序号 | 内 容 | 页码 | | --- | --- | --- | | 1 | 审计报告 | 1-6 | | 2 | 合并资产负债表 | 7 | | 3 | 合并利润表 | 8 | | 4 | 合并现金流量表 | 9 | | 5 | 合并所有者权益变动表 | 10-11 | | 6 | 母公司资产负债表 | 12 | | 7 | 母公司利润表 | 13 | | 8 | 母公司现金流量表 | 14 | | 9 | 母公司所有者权益变动表 | 15-16 | | 10 | 财务报表附注 | 17-112 | 审 计 报 告 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 外经贸大厦 15 层 / 922-926 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 容诚审字[2024]251Z000 ...

非经营性资金占用及其他关联资金 往来情况专项说明 威海百合生物技术股份有限公司 容诚专字[2024]251Z0001 号 容诚会计师事务所(特殊普通合伙) 中国·北京 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 外经贸大厦 15 层 / 922-926 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn 关于威海百合生物技术股份有限公司 非经营性资金占用及其他关联资金往来情况专项说明 容诚专字[2024]251Z0001 号 威海百合生物技术股份有限公司全体股东： 我们接受委托，依据中国注册会计师审计准则审计了威海百合生物技术股份 有限公司（以下简称百合股份）2023 年 12 月 31 日的合并及母公司资产负债表， 2023 年度的合并及母公司利润表、合并及母公司现金流量表和合并及母公司所有 者权益变动表以及财务报表附注，并于 2024 年 4 月 11 日出具了容诚审字 [2024]251Z0003 号的无保留意见审计报告。 根据中国证券监督管理委员会《上市公司监管指引第 8 号——上 ...

2023 年度内部控制评价报告 威海百合生物技术股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内 ...

证券代码：603102 证券简称：百合股份 公告编号：2024-010 威海百合生物技术股份有限公司 关于修订《公司章程》及公司部分治理制度的公告 | | 第一百二十七条 提名委员会成员为 人，全 3 | | --- | --- | | | 部由董事组成，其中 2 人为独立董事。 | | | 提名委员会负责拟定董事、高级管理人员的 | | 第一百二十七条 提名委员会的主要职责是： | 选择标准和程序，对董事、高级管理人员人 | | （一）研究董事、高级管理人员的选择标准 | 选及其任职资格进行遴选、审核，并就下列 | | 和程序并提出建议； | 事项向董事会提出建议： | | （二）广泛搜寻合格的董事和高级管理人员 | （一）提名或者任免董事； | | 的人选； | （二）聘任或者解聘高级管理人员； | | （三）对董事候选人和高级管理人员人选进 | （三）法律、行政法规、中国证监会规定和 | | 行审查并提出建议。 | 公司章程规定的其他事项。 | | | 董事会对提名委员会的建议未采纳或者未完 | | | 全采纳的，应当在董事会决议中记载提名委 | | | 员会的意见及未采纳的具体理由，并进行披 | | ...

威海百合生物技术股份有限公司 章 程 | | | 第二条 公司系依照《公司法》和其他有关规定由荣成百合生物技术有限 公司整体变更并以发起设立方式设立；公司在威海市市场监督管理局注册登记， 现持有统一社会信用代码为 913710007823210514《营业执照》。 第三条 公司于 2022 年 1 月 7 日经中国证券监督管理委员会（以下简称"中 国证监会"）核准，首次向社会公众发行人民币普通股 1,600 万股，于 2022 年 1 月 25 日在上海证券交易所（以下简称"上交所"）主板上市。 第四条 公司注册名称：威海百合生物技术股份有限公司 英文名称：Weihai Baihe Biology Technological Co., Ltd 第五条 公司住所：荣成市天鹅湖经济技术开发区成大路 552 号。 第六条 公司注册资本为人民币 6,400 万元。 第七条 公司为永久存续的股份有限公司。 第八条 董事长为公司的法定代表人。 | 第一章 | 总则 2 | | --- | --- | | 第二章 | 经营宗旨和范围 3 | | 第三章 | 股份 3 | | 第一节 | 股份发行 3 | | | 第二节 股 ...

威海百合生物技术股份有限公司 独立董事工作细则 第一章 总则 第一条 为进一步完善威海百合生物技术股份有限公司（以下简称"公司"） 治理结构，促进公司的规范运作，维护公司及股东特别是中小股东的合法权益， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司独立董事 管理办法》、《上市公司治理准则》、《上海证券交易所股票上市规则》（以下简称 "《股票上市规则》"）、《上海证券交易所上市公司自律监管指引第 1 号-规范运 作》和《上市公司独立董事履职指引》等法律、法规、规范性文件及《威海百合 生物技术股份有限公司章程》（以下简称"公司章程"）的有关规定，制订本细则。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与其所受聘 的公司及公司主要股东、实际控制人不存在直接或者间接利害关系，或者其他可 能妨碍其进行独立客观判断的关系的董事。 独立董事应当独立履行职责，不受公司主要股东、实际控制人、或者其他与 公司存在利害关系的单位或个人的影响。 第三条 独立董事对公司及全体股东负有诚信与勤勉义务。独立董事应按 照相关法律、法规、规范性文件和公司章程的要求，认真履行职责，在董事会中 发挥参与决策、监督 ...